The role of the HGF/Met axis in mesothelioma

Author:

Thayaparan Thivyan1,Spicer James F.12,Maher John134

Affiliation:

1. King's College London, King's Health Partners Integrated Cancer Centre, Department of Research Oncology, Guy's Hospital Campus, Great Maze Pond, London SE1 9RT, U.K.

2. Department of Medical Oncology, Guy's and St Thomas' Hospital, NHS Foundation Trust, Great Maze Pond, London SE1 9RT, U.K.

3. Department of Immunology, Royal Free NHS Foundation Trust, Barnet Hospital, Hertfordshire EN5 3DJ, U.K.

4. Department of Clinical Immunology and Allergy, King's College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, U.K.

Abstract

Malignant mesothelioma is an asbestos-related cancer that occurs most commonly in the pleural space and is incurable. Increasing evidence suggests that aberrant receptor tyrosine kinase (RTK)-directed signalling plays a key role in the pathogenesis of this cancer. In the majority of mesotheliomas, up-regulated expression or signalling by Met, the receptor for hepatocyte growth factor (HGF) can be demonstrated. Following binding of ligand, Met relays signals that promote cell survival, proliferation, movement, invasiveness, branching morphogenesis and angiogenesis. Here we describe the HGF/Met axis and review the mechanisms that lead to the aberrant activation of this signalling system in mesothelioma. We also describe the cross-talk that occurs between HGF/Met and a number of other receptors, ligands and co-receptor systems. The prevalent occurrence of HGF/Met dysregulation in patients with mesothelioma sets the scene for the investigation of pharmaceutical inhibitors of this axis. In light of the inter-relationship between HGF/Met and other ligand receptor, combinatorial targeting strategies may provide opportunities for therapeutic advancement in this challenging tumour.

Publisher

Portland Press Ltd.

Subject

Biochemistry

Reference64 articles.

1. Malignant pleural mesothelioma: an epidemiological perspective;Robinson;Ann. Cardiothorac. Surg.,2012

2. The expected burden of mesothelioma mortality in Great Britain from 2002 to;Hodgson;Br. J. Cancer,2005

3. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada;van Meerbeeck;J. Clin. Oncol.,2005

4. Malignant pleural mesothelioma: current and future perspectives;Porpodis;J. Thorac. Dis.,2013

5. Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells;Sekido;Cancer Sci.,2010

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3